The Spanish Cancer Association (AECC) has granted aid worth one million euros in five years to an advanced endometrial cancer research project involving five cooperative clinical and basic research groups, among which is MD Anderson Foundation Spain, led by Dr. Gema Moreno-Bueno, Senior Advisor at the Translational Research Laboratory at MD Anderson Foundation Spain.
The project, coordinated by Dr. Xavier Matias-Guiu, of the Bellvitge Biomedical Research Institute (Idibell-ICO), seeks to determine the molecular basis of endometrial cancer in advanced stages with the aim of identifying biomarkers that can be subsequently translated into the development of effective treatments for these patients. Endometrial cancer, with an incidence of between 10 and 20 people per 100,000, is the most frequent gynecological tumor among women and, when the disease is in advanced stages, the prognosis is quite bad.
In addition to the ICO-Idibell and MD Anderson Foundation Spain together with the Autonomous University of Madrid (UAM), the project also includes the Health Research Institute of Santiago de Compostela (IDIS), the Research Institute of the Vall d’Hebron University Hospital and the Health Research Institute of the Ramon y Cajal University Hospital (IRYCIS).
The cooperative group, which has been working since 2011 when it received the first aid from the AECC, will continue to collaborate thanks to this new concession, which will allow them to be consolidated as a multidisciplinary group, whose common aim and challenge is to "advance in the knowledge of the basics of endometrial cancer and transfer their findings to the clinic to consolidate the diagnosis and treatment of this disease".